This information was given by the representatives of DHG Pharmaceutical Joint-stock Company at Annual General Meeting of Shareholders 2021 held on March 18th.
In 2021, the Covid-19 epidemic brought many challenges for Vietnam's pharmaceutical industry; but with rapid adaptation DHG Pharma still achieves its business goals and continuously receives more prestigious awards, continues to maintain the leading position of Vietnam's pharmaceutical industry with net revenue of VND 4.003 billion and profit after tax of $776 billion.
In 2022, DHG Pharma sets up a business target with net revenue of VND 4.220 billion and profit before tax of VND 853 billion including key strategies such as:
Board of Directors of DHG Pharma at the 2021 Annual General Meeting of Shareholders.
About increasing revenue: Strengthen the build of corporate brand and brands for key products; strengthen product portfolios and promote the development of new products; expand the market, increase loyal customers, and improve the efficiency of sales activities in major cities; upgrade production lines according to global GMP standards.
Chairperson of the presiding committee of the 2021 Annual General Meeting of Shareholders
About human development: Develop and improve the quality of human resources with high level of professional knowledge, professional working style and readiness for globalization. Develop a roadmap of career advancement for each position and complete the missing senior personnel.
About sustainable development: being a symbol of human culture in contributing to society to improve everyone’s quality of life in the context that the epidemic is still complicated.
Shareholders participate in voting to pass the contents submitted to the General Meeting of Shareholders.
Also at this general meeting, DHG Pharma submitted to the General Meeting of Shareholders to approve the plan to pay the 2021 dividends by cash at a rate of 35% with an effort to ensure the interests of shareholders even in the context of many difficulties of 2021.
